Compare Invesco NASDAQ 100 ETF (QQQM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $289.35, while Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Invesco NASDAQ 100 ETF pays none, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QQQM | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $812.27 |
52-Week Low | $228.02 | $545.46 |
Market Cap | — | $70.79B |
Enterprise Value | — | $64.74B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $286.58 with minimal daily movement (+0.09%) amid bearish technical signals. The ETF faces headwinds from stretched tech valuations and rising AI competition, though recent Nasdaq-100 additions like SpaceX provide diversification. Technical indicators show oversold conditions with RSI at 22.39, while moving averages signal continued downward pressure.
The outlook remains cautious due to valuation concerns and sector rotation risks. However, the lower 0.15% expense ratio versus QQQ offers cost efficiency for long-term growth exposure. Key risks include AI market saturation and tech sector volatility, balanced by the fund's concentrated exposure to leading U.S. innovation companies.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
